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Abstract
A recombinant baculovirus(vBacORF2) that expressed the full-length ORF2 capsid protein of a genotype 1 strain of
hepatitis E virus(HEV) was constructed. Transduction of S10-3 human hepatoma cells with this baculovirus led to
large amounts of ORF2 protein production in ~50% of the cells as determined by immune fluorescence
microscopy. The majority of the ORF2 protein detected by Western blot was 72 kDa, the size expected for the full-
length protein. To determine if the exogenously-supplied ORF2 protein could transencapsidate viral genomes, S10-
3 cell cultures that had been transfected the previous day with an HEV replicon of genotype 1 that contained the
gene for green fluorescent protein(GFP), in place of that for ORF2 protein, were transduced with the vBacORF2
virus. Cell lysates were prepared 5 days later and tested for the ability to deliver the GFP gene to HepG2/C3A cells,
another human hepatoma cell line. FACS analysis indicated that lysates from cell cultures receiving only the GFP
replicon were incapable of introducing the replicon into the HepG2/C3A cells whereas ~2% of the HepG2/C3A
cells that received lysate from cultures that had received both the replicon and the baculovirus produced GFP.
Therefore, the baculovirus-expressed ORF2 protein was able to trans-encapsidate the viral replicon and form a
particle that could infect naïve HepG2/C3A cells. This ex vivo RNA packaging system should be useful for studying
many aspects of HEV molecular biology.
Findings
Hepatitis E virus (HEV) causes acute hepatitis which has
an overall fatality rate of about 2% [1,2]: however, in
developing countries, hepatitis E mortality rates may
approach 20% in pregnant women [3,4]. HEV, currently
t h eo n l ym e m b e ro ft h ef a m i l yHepeviridae,i sc l a s s i f i e d
into 4 genotypes. Genotypes 1 and 2 infect only humans
and non-human primates whereas genotypes 3 and 4
are zoonotic and infect swine and some other mammals
in addition to humans [5]. The HEV genome is a linear,
single-stranded, positive sense RNA of ~7.2 kb. It con-
tains 3 open reading frames (ORFs) [6,7]. ORF1 encodes
a non-structural polyprotein essential for virus replica-
tion. ORF3 codes for a very small protein which has
putative regulatory functions [8] and which is required
for release of virus from infected cells [9]. ORF2
encodes the viral capsid protein; although the full-length
capsid protein consists of 660 amino acids, the apparent
susceptibility of ORF2 protein to proteolytic cleavage
means the size of the protein in virions is not known.
The size of ORF2 protein varies when over-expressed in
insect or mammalian cells and ORF2 products of 52-84
kDa have been reported [10-13]. A truncated ORF2 pro-
t e i n ( 5 3k D a )e x p r e s s e di ni n s e c tc e l l sw a ss h o w nt o
assemble into empty capsids with a T1 symmetry [11]
and an almost full-length ORF2 protein produced in
insect cells was found to assemble into virus particles
with T3 symmetry; these particles captured some of the
ORF2-encoding mRNA [14]. However, trans-encapsida-
tion of infectious virion RNA by over-expressed recom-
binant ORF2 protein has not been reported. HEV has
been difficult to grow in cell culture and although recent
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occurred [15,16], each virus isolate requires adaptation
by lengthy passage in cell culture to grow efficiently.
Additionally, comparable systems for genotypes 1 and 2
have yet to be developed. Therefore, it would be useful
to have a means of producing infectious virions of HEV
by a process that did not require lengthy adaptation to
cell culture
In the present report, we investigated whether
recombinant baculovirus-mediated trans-complementa-
tion with HEV capsid protein could lead to packaging
of an HEV replicon and its subsequent transmission to
naive hepatoma cells. ORF2 and ORF3 are translated
from a bicistronic, subgenomic mRNA. Therefore, pro-
duction of either protein can be used as an indirect
indicator of viral replication. In the present case, the
ORF2 coding sequence had been substituted with that
of green fluorescent protein (GFP) and GFP produc-
tion was used to monitor viral replication [17]. Cul-
tures of human S10-3 and HepG2/C3A cells [18,19]
and insect Sf9 cells (Novagen) [20] were maintained as
previously described. S10-3 cells were seeded (0.5 ×
10
6 cells/well, in triplicate), in a 12-well culture plate.
The BglII-linearized pSK-GFP (SAR55 HEV replicon)
was transcribed in vitro(Figure 1) and transfected into
S10-3 cells, essentially as described elsewhere [18].
Cells were incubated at 34.5°C with 5% CO2 and
observed by fluorescence microscopy (FM)(Zeiss) for
GFP production. Approximately 50% of the cells con-
tained detectable GFP at day 6(data not shown). A
recombinant baculovirus over-expressing ORF2 protein
was constructed by inserting SAR55 HEV sequences
encoding ORF3/ORF2, nt. 5130-7204 into the
pTriEx1.1 vector (Novagen) at the NcoI and BglII sites,
in frame with the vector start codon. Expression
of ORF2 from the final transfer vector, pTriEx-ORF2
(~7.3 kb) was further directed by deleting the
upstream ORF3 start codon sequences by polymerase
chain reaction-based site-directed mutagenesis(TaKaRa
Bio Inc). Plaques of recombinant baculo-ORF2 virus
(vBacORF2) were isolated from Sf9 monolayers accord-
ing to the manufacturer’s instructions (BacVector kit,
Novagen). vBacORF2 were amplified and a virus stock
(10
7 pfu/μl) was prepared by pelleting the virus
through a 5% and onto a 40% sucrose cushion (pre-
p a r e di n1 ×P B S )i naS W 2 8B e c k m a nr o t o ra t2 6 , 0 0 0
rpm [20]. S10-3 cells were transduced at a multiplicity
of infection (moi) of 100, as described previously [20],
except that OptiMem(Invitrogen) was substituted for
serum-free DMEM. The next day, S10-3 cells were re-
seeded in duplicate in 8-chamber glass slides in com-
plete medium and incubated at 37°C. Cells were
immune-stained on days 2 and 5 with primary anti-
ORF2 (chimp1313-sera) and secondary antibody-conju-
gate (Alexa Fluor 488 goat anti-human IgG, Molecular
Probes) as described previously [18]. The slides were
mounted (VECTASHIELD HardSet Mounting Medium
with DAPI, Vector Laboratories) and observed with the
25× objective of an indirect fluorescence microscope
(IFM)(Zeiss) and a FITC filter. A very high level of
HEV capsid protein was detected in ~50% of trans-
duced cells (Figure 2).
Western blot (WB) analysis was performed at days 2
and 5 post-transduction to confirm the molecular mass
of the ex vivo expressed ORF2 protein and to validate
its integrity. Briefly, pelleted S10-3 cells from one well
of a 12-well plate were lysed by vortexing in 90 μl
water, then 10 μl of 10× PBS plus 7.1 μlo fa2 5 %s o l u -
tion of NP40 were added and the lysate was incubated
for 10 min at room temperature. The lysates were
cleared at 15,600 × g and stored at -20°C. Additionally,
the pTriEx-ORF2 vector was transcribed and translated
Figure 1 In vitro transcription of HEV genomic replicon.T h e
BglII-linearized plasmid, pSK-GFP(replicon), (5 μg) was transcribed in
a5 0μl reaction volume and cooled on ice. A 2.5 μl of the RNA
mixture was checked for RNA integrity and semi-quantitation on a
1% agarose gel, containing ethidium bromide. DNA. mr.(standard
DNA marker); Neg.cont.(negative control).
Figure 2 Expression of HEV ORF2 in vBacORF2-transduced S10-
3 cells. Immune-staining(primary anti-ORF2 and secondary Alexa
Fluor 488 goat anti-human IgG) of S10-3 cells at day 5 post-
transduction, showing over-expression of ORF2 protein.
Parvez et al. Virology Journal 2011, 8:159
http://www.virologyj.com/content/8/1/159
Page 2 of 6in vitro in a 50 μl reaction volume (TNT-Coupled
Reticulocyte Lysate System, Promega) as per manufac-
turer’s instructions and stored at -20°C. Twenty four μl
of each sample (in vitro and ex vivo preparations), was
denatured in NuPAGE SDS buffer and reducing agent
(Invitrogen). The protein samples were subjected to
electrophoresis on a NuPAGE 7% Tris-acetate polya-
crylamide gel (Invitrogen) followed by transfer onto a
nitrocellulose membrane(Invitrogen). Blocking and
antibody detection steps were performed, using the
Snap i.d. protein detection system (Millipore). The
membrane was washed in StartingBlock-TBS (Milli-
pore) plus 1% Tween-20(Pierce), and incubated with
chimp1313 anti-ORF2 sera for 10 min at RT followed
by overnight incubation at 4°C. The blot was washed
and further incubated with AffiniPure peroxidase-con-
j u g a t e dr a b b i ta n t i - h u man IgG(Jackson Immuno
Research) for 10 min at RT, followed by treatment
with SuperSignal West Femto Maximum Sensitivity
Substrate(Thermo Scientific). The blot was subse-
quently exposed to an X-ray film (Kodak) and devel-
oped. The WB of in vitro translated ORF2 showed a
~72 kDa product that co-migrated with the ex vivo
p r o d u c te x p r e s s e da td a y2( F i g u r e3 ) .L y s a t ef r o md a y
5 post-transduction also contained a smaller band of
~55 kDa that was assumed to represent a processed
form of 72 kDa protein (data not shown), in line with
earlier reports [10-13].
Controls were performed to demonstrate that baculo-
virus-expressed ORF2 protein and replicon-expressed
GFP could be detected in the same culture. S10-3 cells
were transduced one day after transfection with the
replicon. As observed by fluorescence microscopy at day
6, the replicon-transfected cells expressed GFP while the
mock-transfected and vBacORF-transduced cells were
negative for green fluorescence (Figure 4A). Cell cul-
tures that received both the replicon and vBacORF2 or
vBacORF2 alone, were immunostained for ORF2 protein
and an estimated 50% cells were positive on day 6
(Figure 4B). Note that the acetone fixation step in the
IFM procedure destroyed the GFP signal. FACS analysis
for GFP expression demonstrated that the assay was
specific for GFP and that baculovirus transduction did
not change the number of cells expressing GFP. S10-3
cells in a 24-well plate were harvested at day 5 post-
transduction by treatment with 100 μl trypsin (Invitro-
gen) per well followed by 200 μl of 1 × PBS. Wells were
rinsed with 200 μl more PBS and liquids were pooled
(~500 μl/tube, final). The cells were pelleted at 4°C, and
re-suspended in 300 μl of cold PBS on ice. The samples
were immediately subjected to flow cytometry and a
total of 10,000 cells were counted for every sample (Fig-
ure 4C). The FACS analysis demonstrated that about
16% of the cells were GFP positive whether or not the
cells were transduced (Figure 4D).
In order to determine if the exogenous ORF2 protein
expressed from the baculovirus could trans-encapsidate
the GFP replicon, infectivity assays were performed with
HepG2/C3A cells, the cells most permissive for HEV
infection [19]. Cell lysates of transfected and transduced
S10-3 cell cultures were prepared in duplicate in 200 μl
as described above. Medium was removed from the
HepG2/C3A cells and the total cleared cell lysate from
each tube was added to an assigned well. Cells were
incubated at 37°C for 2.5 hrs with periodic rocking
every 15 min. The inoculum was replaced with complete
medium and incubation was continued for 6 days. FM
observations suggested that the S10-3 cells that received
lysates from cells containing both replicon RNA and
vBacORF2 expressed GFP in about 5% of naïve HepG2/
C3A cells on day 6 post-infection (Figure 5A). On the
other hand, lysates from cells receiving replicon alone or
vBacORF2 alone, were not able to infect HepG2/C3A
cells since at day 6, GFP was not detected. Quantifica-
tion of GFP-containing HepG2/C3A cells by FACS ana-
lysis confirmed the FM results (Figure 5B). Lysates from
cells transfected with replicon and later transduced,
infected 2% of the HepG2/C3A cells whereas lysates
from mock-transfected, replicon-transfected, or vBa-
cORF2-transduced cells did not induce GFP production
in HepG2/C3A cells (Figure 5C). The replicon-only
lysate control ruled out the possibility that unencapsi-
dated residual transfecting RNA was responsible for
GFP production in the HepG2/C3A cells. Therefore,
these results clearly demonstrated that exogenously-
supplied ORF2 protein is able to trans-complement a
Figure 3 In vitro and ex vivo expression of full length ORF2
protein. WB analysis, showing in vitro (TNT coupled transcription-
translation of pTriEx-ORF2) as well as ex vivo (day 2, post-
transduction with vBacORF2) translations of full length ORF2 (~72
kDa band). Std. mr.(standard protein marker); Neg.cont.(negative
control).
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thereby produce intracellular virions that are infectious
for cultured cells.
Our results are consistent with the recent report by
Xing et al. [14] that HEV virus-like particles formed in
insect cells captured some of the template ORF2 RNA
used to produce the particles. Whether this capture was
fortuitous, specific, or efficient is unclear. In our case,
although we were able to infect only 2% of the HepG2/
C3A cells, this represented a reasonably efficient packa-
ging of replicon RNA; encapsidation absolutely required
co-expression of adequate levels of ORF2 protein and
replicon RNA and only 16% of the S10-3 cells contained
a functional replicon(Figure 3C) and an estimated 50%
contained ORF2 protein. It should be possible to
improve the system by further optimizing transfection
or transduction parameters but in the meantime our
results provide proof-of-principal for trans-encapsidation
of HEV genomes by ORF2 and confirm the previous
reports that ORF3 protein is not required for generation
of infectious virions [18,21]. This trans-encapsidation
system should be useful for providing substrates for ana-
lysis of neutralizing antibodies or for determining para-
meters that are necessary for encapsidation of viral
RNA, such as packaging signals in the RNA or critical
regions or residues in the ORF2 protein.
Conclusions
This is the first demonstration that the HEV full-length
ORF2 protein is efficiently expressed by baculovirus-
transduced hepatoma cells. The ORF2 protein
trans-complements a replicon that is deficient in capsid
protein production and efficiently encapsidates the repli-
con viral RNA to form stable HEV particles which are
Figure 4 Co-expression of ORF2 and GFP proteins in HEV replicon-transfected cells in a culture. (A) FM, showing GFP expression in cells
at day 6 post-transfection. (B) IFM, showing ORF2 expression in cells at day 5 post-transduction. (C) FACS plot, showing expression of GFP in
cells at day 6. (D) %GFP positive cells in C, determined by FACS.
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packaging-system could be further used to study many
aspects of HEV molecular biology.
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